Clovis Oncology Gets FDA Approval for New Ovarian Cancer Drug

A new treatment has been approved by the FDA for treatment of ovarian cancer. The treatment is made by Clovis Oncology.
Publish date:

Clovis Oncology ( (CLVS) - Get Report ) won approval today for its new ovarian cancer drug known as Rubraca. According to the FDA, the drug is approved to treat women with advanced ovarian cancer who have been treated with two or more chemotherapies and whos tumors have a specific gene mutation known as BRCA. The agency approved Rubraca under its accelerated approval program. The National Cancer Institute estimates that more than 22,000 women will be diagnosed with ovarian cancer in 2016 and an estimated 14,000 will die of this disease. Approximately 15 to 20 percent of patients with ovarian cancer have a BRCA gene mutation.